BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11914913)

  • 1. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
    Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
    Jansen WJ; Zwart B; Hulscher ST; Giaccone G; Pinedo HM; Boven E
    Int J Cancer; 1997 Jan; 70(3):335-40. PubMed ID: 9033637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.
    Wu MH; Yan B; Humerickhouse R; Dolan ME
    Clin Cancer Res; 2002 Aug; 8(8):2696-700. PubMed ID: 12171903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.
    Wierdl M; Wall A; Morton CL; Sampath J; Danks MK; Schuetz JD; Potter PM
    Mol Pharmacol; 2003 Aug; 64(2):279-88. PubMed ID: 12869632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse liver and kidney carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-terminal three quarter sequence determines substrate selectivity.
    Xie M; Yang D; Wu M; Xue B; Yan B
    Drug Metab Dispos; 2003 Jan; 31(1):21-7. PubMed ID: 12485949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
    Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
    Xu G; Zhang W; Ma MK; McLeod HL
    Clin Cancer Res; 2002 Aug; 8(8):2605-11. PubMed ID: 12171891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
    Tobin P; Clarke S; Seale JP; Lee S; Solomon M; Aulds S; Crawford M; Gallagher J; Eyers T; Rivory L
    Br J Clin Pharmacol; 2006 Jul; 62(1):122-9. PubMed ID: 16842384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Mishra MN; Vangara KK; Palakurthi S
    Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
    Hennebelle I; Terret C; Chatelut E; Bugat R; Canal P; Guichard S
    Anticancer Drugs; 2000 Jul; 11(6):465-70. PubMed ID: 11001387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
    Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
    Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
    Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
    J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
    Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
    Azzariti A; Xu JM; Porcelli L; Paradiso A
    Biochem Pharmacol; 2004 Jul; 68(1):135-44. PubMed ID: 15183125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.
    Xiao D; Yang D; Guo L; Lu W; Charpentier M; Yan B
    Br J Pharmacol; 2013 Apr; 168(8):1989-99. PubMed ID: 23373735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
    Jandu H; Aluzaite K; Fogh L; Thrane SW; Noer JB; Proszek J; Do KN; Hansen SN; Damsgaard B; Nielsen SL; Stougaard M; Knudsen BR; Moreira J; Hamerlik P; Gajjar M; Smid M; Martens J; Foekens J; Pommier Y; Brünner N; Schrohl AS; Stenvang J
    BMC Cancer; 2016 Jan; 16():34. PubMed ID: 26801902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
    Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
    Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours.
    Tobin PJ; Dodds HM; Clarke S; Schnitzler M; Rivory LP
    Oncol Rep; 2003; 10(6):1977-9. PubMed ID: 14534729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
    Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.
    Pavillard V; Charasson V; Laroche-Clary A; Soubeyran I; Robert J
    Anticancer Res; 2004; 24(2B):579-85. PubMed ID: 15160997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.